Metropolis Healthcare Q2FY26 Revenue Rises 23% YoY on Strong Wellness Segment; Stock Up 2.75%

Mumbai, October 7, 2025: Metropolis Healthcare Ltd (NSE: METROPOLIS, BSE: 542650) has reported preliminary results for the second quarter of the current financial year. The company has reported a strong 23% year-on-year growth in revenue (consolidated). This is largely due to the strong momentum in the TruHealth Wellness and Specialty Testing offerings as per the business update.

The share started strong on Tuesday morning and was trading 2.75% higher from the previous day’s close (around ₹2130 per share) after hitting an intraday high of ₹2160 before consolidating a bit at 10:45 AM, when the stock traded at ₹2113.50 (1.95% higher from the previous day’s closing price). The stock is now trading closer to its 52-week high of ₹2318 and has surged more than 6% in the past week.

Key Financial Highlights (Q2FY26)

The quarterly report was quite strong, with the total revenue rising 23% (year on year). Furthermore, standalone revenue also increased by 12% as the number of patients and test volumes rose. The TrueHealth Wellness segment soared 25%, largely due to increased demand for preventive health check-ups. On the other hand, the Specialty segment advanced by 36% due to strong traction in diagnostics. There was an increase in both B2C and B2B revenues (16% and 34% respectively).

The company achieved improved EBITDA margins QoQ through synergies and operating leverage, and maintained a debt-free balance sheet with ₹55 crore in net cash.

Business and Strategic Updates

The company had acquired Core Diagnostics, which moved from break-even in the previous financial year to a high single-digit profitability in the second quarter of the current financial year. Scientific Pathology (Agra) and Dr. Ahuja’s Pathology & Imaging Center (Dehradun) also contributed to the company’s profitability through above-average margins. Further, the company acquired Dr. R.S. Patil’s Ambika Pathology Laboratory, Kolhapur, for establishing a mini reference lab for Western Maharashtra, thereby expanding its regional coverage.

Management Commentary

The company underlined that a lower occurrence of vector-borne illnesses such as dengue and malaria has not affected the resilience of the diversified portfolio of services offered, and there is a growing focus on preventive wellness and lifestyle healthcare.

REF: https://nsearchives.nseindia.com/corporate/METROPOLIS_06102025160746_SE_Intimation_Business_Update_Q2FY26.pdf

Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations